dinutuximab

Known as: Ch 14.18UTC, MAb ch14.18, Ch14.18 Monoclonal Antibody 
A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Treatment of high-risk neuroblastoma (NB) represents a major challenge in paediatric oncology. Alternative therapeutic strategies… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
INTRODUCTION Use of copper radioisotopes in antibody radiolabeling is challenged by reported loss of the radionuclide from the… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2010
2010
Monoclonal antibodies against GD(2) ganglioside, such as ch14.18, the human-mouse chimeric antibody, have been shown to be… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
BACKGROUND Advanced (stage 4) cases of neuroblastoma, a childhood cancer of the nervous system, are associated with high relapse… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1996
1996
 A major problem in the treatment of solid tumors is the eradication of established, disseminated metastases. Here we describe an… (More)
  • figure 1
  • figure 2
  • table 2
  • table 1
  • figure 3
Is this relevant?
1994
1994
A genetically engineered fusion protein consisting of a human/mouse chimeric anti-ganglioside GD2 antibody (ch14.18) and… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
1993
1993
Several human cytokines including IL-2, GM-CSF, and tumor necrosis factors alpha and beta were engineered as fusion proteins to… (More)
Is this relevant?
Highly Cited
1992
Highly Cited
1992
A genetically engineered fusion protein consisting of a chimeric anti-ganglioside GD2 antibody (ch14.18) and interleukin 2 (IL2… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1990
1990
Recombinant techniques allow one to engineer an antibody molecule and, in this way, manipulate its properties and functions. We… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?